Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET)

G. Jerusalem, G. Mariani, E. M. Ciruelos, M. Martin, V. C. G. Tjan-Heijnen, P. Neven, J. G. Gavila, A. Michelotti, F. Montemurro, D. Generali, E. Simoncini, I. Lang, J. Mardiak, B. Naume, M. Camozzi, K. Lorizzo, S. Bianchetti, P. Conte

Research output: Contribution to journalArticleAcademicpeer-review

2 Citations (Scopus)
Original languageEnglish
Pages (from-to)1719-1725
Number of pages7
JournalAnnals of Oncology
Volume27
Issue number9
DOIs
Publication statusPublished - Sep 2016

Keywords

  • advanced breast cancer
  • BMI
  • elderly
  • everolimus
  • hormone-receptor positive
  • stomatitis

Cite this

Jerusalem, G., Mariani, G., Ciruelos, E. M., Martin, M., Tjan-Heijnen, V. C. G., Neven, P., Gavila, J. G., Michelotti, A., Montemurro, F., Generali, D., Simoncini, E., Lang, I., Mardiak, J., Naume, B., Camozzi, M., Lorizzo, K., Bianchetti, S., & Conte, P. (2016). Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET). Annals of Oncology, 27(9), 1719-1725. https://doi.org/10.1093/annonc/mdw249